ALL GIMEMA 0904(Active): Treatment of high-risk ALL and MRD-monitoring
ALL GRAALL 02/2005(Active): HyperC vs. standard induction and late intensification in Ph neg. ALL
ALL NILG 09/00(Active): Postremission programme according to MRD
ALL PALG 5-2007 MRD(Active): Optimization of the therapy of adult acute lymphoblastic leukemia according to risk factors and monitoring of minimal residual disease
ALL-NILG 10/07(Active): A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL
ALL-SCT Ph negative(Active): Role of autologous bone marrow transplantation plus maintenance therapy in acute lymphoblastic leukemia in adults.
AML ALFA -0701(Active): A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML)
AML ALFA -0702(Active): The CLARA Study from the Acute Leukemia French Association
AML ALFA -0703(Active): ALFA-0703 Study A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage therapy and Idarubicin with Cytarabine or Azacitidine as Maintenance Therapy in Older Patients with Acute Myeloblastic Leukemia (AML)
AML HEMOS 0106(Active): Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years)
AMLSG 09-09(Active): Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
AMLSG 10-07 FLT3mut-Sunitinib(Active): SU11248 Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML
AMLSG 11-08(Active): Phase Ib/IIa Study For the Evaluation of Dasatinib Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML
LAM-SA 2007(Active): Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-Remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old
LAM07(Active): PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
LAM2006IR(Active): Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
PANOBIDARA(Active): A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
SPARK-AML1(Active): A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ¡Ý 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)
Timed-Sequential Induction in CBF-AML(Active): A Phase 3 Trial of Systematic Versus Response-Adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
AML AraC-IL2(Active): Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
AML HOVON / SAKK - 42A(Active): G-CSF priming in adult patients with acute myelocytic leukemia (AML) or refractory anemia
AML HOVON SAKK 42(Active): Randomized induction + post induction in AML/RAEB/RAEB-T
AML-NILG 02/06(Active): Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program
AMLCG-2000(Active): Biology and therapystrategy of AML an its subgroups
MDS AlloSCT-Clofarabine(Active): Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome or Acute Lymphoblastic Leukemia
MDS CytogenicAnalysis(Active): Cytogenetic Analysis Using Blood and Tissue Samples From Young Patients With Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, or Down Syndrome and Acute Myeloid Leukemia
MDS StemCellTransplant II(Active): Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (FB-ATG)
relapsed/refractory
AML AZD1152(Active): Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
AML CP4055(Active): A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
CML Homoharringtonine(Active): Homoharringtonine in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
de novo/non-treated
CML Imatinib+Zoledronic Acid(Active): Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
NordCML006(Active): A randomized study of imatinib or dasatinib treatment response in CML stem cells in newly diagnosed CML.
CML Dasatinib Vs. Imatinib 400 mg(Active): A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
CML STI571 Spirit(Active): High-dose of Imatinib (STI571) vs. low-dose Imatinib in combination with cytostatics vs. reference-dose of Imatinib (SPIRIT-study)
MDS Bevacizumab(Active): A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts
AML RICMAC/MDSsAML(Active): Dose reduced vs. standard conditioning + SCT in MDS or sAML
AMLCG-2000(Active): Biology and therapystrategy of AML an its subgroups
MDS 5-Azacitidine(Active): Subcutaneous Azacitidine + best supportive care vs. conventional regimens + best supportive care
MDS 5-Azacytidine II(Active): Study of maintenance of response with azacytidine administered subcutaneously for 5 consecutive days every 28 daysfor 24 months in adult subjects with Myelodysplastic syndromes (MDS) in response after intensive chemotherapy
MDS AMG531(Active): AMG531 in low- or intermediate-1 risk MDS with Thrombopenia
MDS AlloSCT-Clofarabine(Active): Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome or Acute Lymphoblastic Leukemia
MDS Azacitidine-Epoetin Beta II(Active): Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
MDS Biomarkers(Active): Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
MDS Bortezomib/Cytarabine(Active): Adult subjects with Myelodysplastic Syndromes (MDS) will receive Bortezomib and Low Dose Cytarabine
MDS CytogenicAnalysis(Active): Cytogenetic Analysis Using Blood and Tissue Samples From Young Patients With Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, or Down Syndrome and Acute Myeloid Leukemia
MDS Exjade(Active): Exjade(ICL670) in transfusion dependent iron overload
MDS Lenalidomide I(Active): Lenalidomide vs Placebo in RBC-dependent low- or intermediate-1 risk MDS with 5q-
MDS NMDSG03A(Active): Effects of anemia in elderly MDS patients, regarding quality of life and cardiac function
MDS Revlimid(Active): Revlimid monotherapy in MDS 5q-
MDS Romiplostim I(Active): Evaluating the Safety of Long Term Dosing of Romiplostim (formerly AMG 531) in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)
MDS Romiplostim II(Active): Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS StemCellTransplant II(Active): Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (FB-ATG)
MDS Velcade(Active): Phase II Study of PS341 (VELCADE) in Myelodysplastic Syndromes (MDS)
